January 12, 2023
During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.
November 28, 2022
Marcia S. Brose, MD, PhD, FASCO, discusses NTRK gene fusions and identifying patients with thyroid cancer.
October 10, 2022
Mark A. Socinski, MD provides insight on biomarker testing to identify patients with NTRK gene fusion-positive non–small cell lung cancer.
September 21, 2022
Alexander Drilon, MD, discusses what community oncologists should know about testing for NTRK gene fusions in patients with solid tumors.
September 14, 2022
The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.
September 14, 2022
David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.
September 06, 2022
In an interview with Targeted Oncologyy, David S. Hong, MD, discussed an updated analysis of larotrectinib and the data supporting the agent for the treatment of TRK fusion-positive lung tumors.
September 04, 2022
David Hong, MD, explains why larotrectinib may be chosen over other TRK inhibitors for the treatment of NTRK fusion-positive lung cancer.
June 22, 2022
Alexander Drilon, MD, discusses targeted therapies for the patients with NTRK gene fusion-positive cancers.
June 07, 2022
At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.